Interventional Glaucoma

The trial is evaluating the company’s femtosecond laser trabeculotomy procedure in comparison to selective laser trabeculoplasty

The SAPPHIRE trial evaluating the VisiPlate is currently underway across several sites across the US, with more site activations scheduled for 2026

The BIM-IOL System is for the treatment of elevated IOP in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma cases.

Surgeons reflect on milestones that have redefined patient care—and share a glimpse of the advances that promise to shape the next era of eye health.

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

From MIGS integration to remote monitoring and next-generation therapeutics, glaucoma specialists explore how new approaches are redefining patient outcomes.

Oluwatosin U. Smith, MD, reflects on early experiences caring for pediatric patients with complex glaucoma and how evolving tools and advancing science have reshaped treatment options over the decades.

The 24-month results of this first-in-human trial supports the potential long-term outcomes of this system to lower IOP.

Providers are rethinking their spaces and systems to streamline care, reduce waste, and improve patient, staff and physician satisfaction

Earlier use of SLT, sustained-release drug delivery, and MIGS is reframing glaucoma care.

Roundtable discussion explores surgical and sustained-release options.

Inder Paul Singh, MD, shares a formative experience in which a patient’s vision loss—and their unexpected gesture of comfort—shaped his approach to high-risk glaucoma care.

Bedrood describes improved visualization of the ciliary body, efficient setup, and favorable postoperative outcomes.

Innovations in selective laser trabeculoplasty and laser cyclophotocoagulation focus on procedural efficiency, patient comfort, and evolving first-line treatment strategies.

In this murine model of glaucoma, SPG302 was administered daily to 3-month-old mice for 8 weeks.

Explore groundbreaking advancements in eye care from the 2000s, including LASIK innovations, anti-VEGF treatments, and enhanced imaging technologies.

The VisiPlate aqueous shunt is made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair, according to the company.

Explore the groundbreaking advancements in ophthalmic technology from the 1980s and 1990s, including excimer lasers, LASIK, and innovative imaging techniques.

From lasers to lenses, the 1970s redefined vision care through breakthroughs in surgery, imaging, and therapeutics.

Lupin notes that the acquisition will help to strengthen the company by “integrating VISUfarma’s established commercial operations.”

Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.